AC Immune SA
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Values in USD · ADR · Reports in CHF
AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, including five in Phase 2 development and one in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties. SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU. The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.
Did you know?
Holds 5.9x more cash than debt — a strong balance sheet.
Current Price
—
Profile
Valuation (TTM)
Market Cap—
P/E—
EV—
P/B—
Shares Out—
P/Sales—
Revenue—
EV/EBITDA—
AC Immune SA (ACIU) Stock Analysis
Market Cap—
Current Price—
P/E Ratio—
Forward P/E—
PEG Ratio—
EPS—
Book Value—
P/B Ratio—
ACIU Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Cash: 28M
Revenue
114M
FY19
18M
FY20
—
FY21
4M
FY22
18M
FY23
30M
FY24
5M
FY25
Net Income
47M
FY19
—
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
Did you know?
ACIU's revenue grew at a -41.6% CAGR over the last 6 years.
AC Immune SA (ACIU) Financial Summary
AC Immune SA (ACIU) is a Healthcare company in the Biotechnology industry, listed on NASDAQ..
..
ACIU Key Financial Metrics
| Metric | Value |
|---|
ACIU Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $113.87M | $46.85M |
| FY20 | $17.54M | $-70.36M |
| FY21 | $0.00 | $-80.22M |
| FY22 | $4.23M | $-76.08M |
| FY23 | $17.62M | $-64.56M |
| FY24 | $30.34M | $-56.57M |
| FY25 | $4.52M | $-89.17M |
About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, including five in Phase 2 development and one in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties. SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU. The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.